CoChat
Sign Up
Cited by 72MicroRNA in disease regulationCancer-related molecular mechanisms researchCervical Cancer and HPV Research

The DOI matches its Crossref record; the references it cites are not checked yet.

MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4

Open access
Zhang, Zhan, Wang, Jinming, Li, Jing, Wang, Xiaofang, Song, Wanyu·2018·Biomedicine & Pharmacotherapy
DOI 10.1016/j.biopha.2017.09.143
Open this paper in CoChat — free accountOpen PDF

Abstract

Recent studies have showed that microRNA-150 (miR-150) is up-regulated in various cancers including cervical cancer. However, the specific mechanism of miR-150 in the regulation of cell proliferation, migration and invasion is still unclear. In this study, a total of 150 cervical cancer samples, including 50 cervical cancer tissues, 50 corresponding adjacent non-neoplastic tissues, and 50 serum samples were collected from cervical cancer patients. 50 matched normal tissues and 50 serum samples were collected from the control group. MiR-150 was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Programmed cell death protein 4 (PDCD4) was evaluated by qRT-PCR and western blot. Cell migration and invasion were assessed by transwell assays. Proliferative abilities were determined by MTT assays. Luciferase reporter assay was employed to validate the direct target of PDCD4 by miR-150. We found that miR-150 was increased in cervical cancer specimens. In contrast, PDCD4 was decreased in cervical cancer tissues. MiR-150 promoted cell migration, invasion and proliferation through targeting PDCD4. These results collectively indicated that miR-150 might be used as a potential therapeutic biomarker in cervical cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2017.09.143

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 24 · Cited by 72

Research works printed but not linked: 25

  1. Monk, 2009, A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC), J. Clin. Oncol., 27, 5520, 10.1200/jco.2009.27.15_suppl.5520 · DOI
  2. Movva, 2009, Expression of the epidermal growth factor receptor (EGFR) pathway in cervical cancer (CC) patients (pts), J Clin Oncol, 27, 5519, 10.1200/jco.2009.27.15_suppl.5519 · DOI
  3. Lecuru, 2009, Impact of sentinel lymph node biopsy on staging of early cervical cancer: results of a prospective, multicenter study, J. Clin. Oncol., 27, A5506, 10.1200/jco.2009.27.18_suppl.cra5506 · DOI
  4. Kim, 2015, Clinical significance of OCT4 and SOX2 protein expression in cervical cancer, BMC Cancer, 15, 1015, 10.1186/s12885-015-2015-1 · DOI
  5. Pedroza-Torres, 2016, A microRNA expression signature for clinical response in locally advanced cervical cancer, Gynecol. Oncol., 142, 557, 10.1016/j.ygyno.2016.07.093 · DOI
  6. Zhang, 2017, miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway, Biomed. Pharmacother., 85, 472, 10.1016/j.biopha.2016.11.053 · DOI
  7. Pedroza-Torres, 2016, A microRNA expression signature for clinical response in locally advanced cervical cancer, Gynecol. Oncol., 142, 557, 10.1016/j.ygyno.2016.07.093 · DOI
  8. Kayano, 2016, Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis, Biomark Res., 4, 22, 10.1186/s40364-016-0076-1 · DOI
  9. Fang, 2016, miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways, Cell. Death. Dis., 7, 2371, 10.1038/cddis.2016.256 · DOI
  10. Jiang, 2016, Eradication of acute myeloid leukemia with FLT3 ligand-Targeted miR-150 nanoparticles, Cancer Res., 76, 4470, 10.1158/0008-5472.CAN-15-2949 · DOI
  11. Aherne, 2015, Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression, BMC Cancer, 15, 329, 10.1186/s12885-015-1327-5 · DOI
  12. Lei, 2014, miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro, Med. Sci. Monit., 20, 1850
  13. Zhu, 2016, Ischemic postconditioning-regulated miR-499 protects the rat heart against ischemia/reperfusion injury by inhibiting apoptosis through PDCD4, Cell. Physiol. Biochem., 39, 2364, 10.1159/000452506 · DOI
  14. Frampton, 2015, Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression, Lancet, 385, 37, 10.1016/S0140-6736(15)60352-X · DOI
  15. Pereira, 2013, Delivering the promise of miRNA cancer therapeutics, Drug Discov. Today, 18, 282, 10.1016/j.drudis.2012.10.002 · DOI
  16. Garajova, 2015, MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy, Clin Epigenetics, 7, 129, 10.1186/s13148-015-0162-5 · DOI
  17. Huang, 2013, miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2×7 receptor, PLoS One, 8, 80707, 10.1371/journal.pone.0080707 · DOI
  18. Li, 2015, microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4, BMC Mol. Biol., 16, 24, 10.1186/s12867-015-0052-6 · DOI
  19. Yokobori, 2013, MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1, Cancer Sci., 1, 48, 10.1111/cas.12030 · DOI
  20. Fang, 2016, miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways, Cell. Death. Dis., 7, 2371, 10.1038/cddis.2016.256 · DOI
  21. Begum, 2015, An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: clinical significance of miR-23b-3p deregulation, Sci. Rep., 5, 13236, 10.1038/srep13236 · DOI
  22. Jayawardana, 2016, Identification, review, and systematic cross-validation of microRNA prognostic signatures in metastatic melanoma, J. Invest. Dermatol., 136, 245, 10.1038/JID.2015.355 · DOI
  23. Fleming, 2015, Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients, Cancer, 121, 51, 10.1002/cncr.28981 · DOI
  24. Zhu, 2016, Ischemic postconditioning-Regulated miR-499 protects the rat heart against ischemia/reperfusion injury by inhibiting apoptosis through PDCD4, Cell. Physiol. Biochem., 39, 2364, 10.1159/000452506 · DOI
  25. Allgayer, 2010, Pdcd4, a colon cancer prognostic that is regulated by a microRNA, Crit. Rev. Oncol. Hematol., 73, 185, 10.1016/j.critrevonc.2009.09.001 · DOI

Metadata

Authors
Zhang, Z., Wang, J., Li, J., Wang, X., & Song, W.
Affiliations
Third Affiliated Hospital of Zhengzhou University (CN)
Corresponding author
Zhang, Zhan
ORCID
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2018-01
Volume
97
Pages
511-517
ISSN
0753-3322 (ISSN-L)
DOI
10.1016/j.biopha.2017.09.143
OpenAlex
W2767350841
Cited by
72
References
24
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 9 · 2019: 12 · 2018: 5
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomedicine & Pharmacotherapy (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Science and Technology Department of Henan Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
miR-150, PDCD4, cervical cancer, cell proliferation, cell migration, cell invasion, microRNA target regulation, therapeutic biomarkers
MeSH terms
Adult, Aged, Cell Movement, Uterine Cervical Neoplasms, Female, HeLa Cells, Humans, Middle Aged, Neoplasm Invasiveness, RNA-Binding Proteins, MicroRNAs, Cell Proliferation, Apoptosis Regulatory Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. https://app.cochat.ai/papers/10.1016/j.biopha.2017.09.143
The paper
Zhang, Z., Wang, J., Li, J., Wang, X., & Song, W. (2018). MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2017.09.143